# US 2016/0256498 A1 · Methods and compositions for treatment of penile defects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256498 A1
- Document ID: US20160256498A1
- Status: Published application
- Kind: A1
- Application number: 15/158,101
- Filed: 2016-05-18
- Published: 2016-09-08
- Earliest claimed: 2012-01-30
- Inventors: Michael P. Zahalsky
- Web page: https://patentgrep.com/patent/US20160256498A1

## CPC

- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/18: Growth factors; Growth regulators
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 27/225: {Fibrin; Fibrinogen}
- A61L 27/24: Collagen
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 15/10: for impotence
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition for use in treating penile defects, including erectile dysfunction and Peyronie's disease, is provided. The composition includes adipose tissue and stem cells. The stem cells may be derived from adipose tissue. In embodiments the composition includes additional additives such as growth factors, anti-inflammatories, antioxidants, compositions useful for wound healing, and collagenases. Also provided is a method of treating a penile defect in a patient. The method includes providing a composition containing adipose tissue and stem cells, and implanting that composition into a patient in need of treatment for a penile defect. In some embodiments the patient has Peyronie's disease. In other embodiments, the patient has erectile dysfunction.

## Claims

### Claim 1

A method of treating a subject with a penile defect comprising the steps of:
providing a composition comprising at least one isolated stem cell; and implanting the composition within the penis of a subject in need of treatment for a penile defect, wherein the at least one stem cell is a mesenchymal stem cell, wherein the mesenchymal stem cell is an ADRC

### Claim 2 (depends on 1)

The method according to claim 1, wherein the adipose tissue and ADRC are derived from the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises a biological scaffolding, wherein the scaffolding is a fibrin scaffolding.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is injected into or around the tunica albuginea.

### Claim 5 (depends on 1)

The method of claim 1, wherein the defect is Peyronie's disease.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises at least one additional agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent promotes at least one of wound healing, angiogenesis, vasculogenesis, and degradation of collagen.

### Claim 8 (depends on 6)

The method of claim 6, wherein the agent is an anti-inflammatory or an antioxidant.

### Claim 9

A method of treating a subject with Peyronie's disease comprising the steps of:
providing a composition comprising at least one isolated mesenchymal stem cell, at least one component of extracellular matrix, and at least one growth factor; and
injecting the composition within the tunica albuginea of a subject in need of treatment for Peyronie's disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one stem cell is a placental stem cell.

### Claim 11 (depends on 3)

The method of claim 3, wherein the scaffold comprises collagen.

### Claim 12

A method of breaking down plaque in a subject with Peyronie's disease comprising the steps of:
providing a composition comprising at least one isolated mesenchymal stem cell, at least one component of extracellular matrix, and at least one growth factor; and
administering the composition to the plaque of a subject in need of treatment for Peyronie's disease.
